Huntington Bancshares
HBAN
$15.27
-0.52%
Huntington Bancshares is a regional US bank holding company with over $280 billion in assets, operating a full suite of consumer deposit and lending services alongside commercial offerings spanning payments, investment management, capital markets, equipment financing, and treasury management. As one of the larger US regional banks, Huntington occupies a scale-advantaged position in its Midwest and mid-Atlantic footprint, competing against money-center banks and smaller community lenders while leaning on fee-based commercial services to differentiate from pure spread lenders. The current investor narrative is dominated by a sharp divergence between reported fundamentals and stock performance: Q2 2026 revenue surged 37.7% year-over-year to $4.17 billion and net income jumped to $727 million, yet the shares have fallen roughly 13% year-to-date and sit near the bottom of their 52-week range. The debate centers on whether the revenue surge — accompanied by a jump in diluted shares outstanding from roughly 1.48 billion to 1.98 billion, signaling acquisition-related dilution — represents durable scale-building or expensive, margin-dilutive expansion, with the stock's 3.96% dividend yield increasingly viewed as either a value signal or a warning about earnings quality.…
HBAN
Huntington Bancshares
$15.27
Investment Opinion: Should I buy HBAN Today?
Rating: Hold. The core thesis is that HBAN offers deep value (1.05x P/B, 3.96% dividend yield, 0.90 PEG) but faces a deteriorating technical trend and unresolved dilution overhang that warrant patience. The analyst consensus is Buy with a mean rating of 1.71 and an average target of $19.17 (+25.5% upside), but the stock's 16.33% three-month decline and proximity to 52-week lows suggest the market is pricing in risks the sell-side may be underestimating.
Supporting evidence includes: (1) a forward PE of 8.66x versus trailing 12.30x, implying ~42% EPS growth to $1.73; (2) revenue growth of 37.66% YoY, though acquisition-driven; (3) a sustainable 45.95% payout ratio backing the 3.96% yield; (4) $2.96 billion in trailing free cash flow, an ~11.5% FCF yield; and (5) a 1.05x P/B versus the 1.3-1.5x peer range. However, ROE of 9.08% and flat net margins offset these positives, and the 33% share dilution is a real overhang.
Key risks that could invalidate the thesis: (1) continued EPS dilution if integration synergies fail, (2) a break below the $14.82 support triggering further selling, and (3) further analyst downgrades. The rating would upgrade to Buy if the stock forms a base above $16.75-17.00 resistance and Q3 EPS shows sequential improvement toward $0.45, or downgrade to Sell if price breaks below $14.82 or net margin falls below 17%. Valuation verdict: fairly valued to slightly undervalued relative to history (P/B near low end of 0.81x-1.20x range) and peers, but the discount is partially justified by below-peer ROE and dilution risk.
Sign up to view all
HBAN 12-Month Price Forecast
HBAN presents a classic value-versus-momentum conflict: deep valuation (1.05x P/B, 0.90 PEG, 3.96% yield) and unanimous analyst Buy ratings clash with a confirmed downtrend and dilution overhang. The forward PE of 8.66x versus trailing 12.30x suggests the market is pricing in significant risk to the $1.73 EPS estimate, and until Q3 results demonstrate margin stabilization and EPS accretion, the stock is likely to remain range-bound. I would upgrade to bullish if the stock reclaims $16.75-17.00 resistance with improving EPS, or downgrade to bearish if it breaks below $14.82 or net margin falls below 17%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Huntington Bancshares's 12-month outlook, with a consensus price target around $19.16 and implied upside of +25.5% versus the current price.
Average Target
$19.16
0 analysts
Implied Upside
+25.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$17 - $23
Analyst target range
Coverage is robust with 20 analysts, and the consensus is decisively bullish: the recommendation is "Buy" with a mean rating of 1.71 (where 1.0 is a Strong Buy), and the average target price of $19.17 implies +25.5% upside from the current $15.27. This creates a stark disconnect — analysts see substantial value while the market has been selling — and the recent institutional ratings show no downgrades to Sell, with Truist, DA Davidson, Evercore ISI, Wells Fargo, and RBC all maintaining Buy/Outperform/Overweight ratings through September 2026. The consensus leans clearly bullish, though the B of A downgrade to Neutral from Buy on July 27 and Morgan Stanley's cut to Equal Weight from Overweight on July 24 suggest some analysts are turning more cautious on the name.\n\nThe target range of $17.00 to $22.50 is relatively wide — a 32% spread from low to high — signaling meaningful uncertainty about the earnings trajectory. The high target of $22.50 would require roughly 47% upside and likely assumes successful integration of the acquisition, margin expansion toward the 23-24% operating levels seen in Q3 2025, and multiple re-rating toward 1.3x book. The low target of $17.00 still implies +11.3% upside and likely prices in continued dilution, flat margins, and a modest recovery to the September resistance zone. Notably, even the low target sits above the current price, meaning no analyst models a downside scenario — a uniformity that itself warrants caution, as it suggests the sell-side may be anchored to pre-decline valuations. The estimated EPS average of $1.73 against trailing EPS of $0.086 (a data artifact of quarterly versus annual reporting) and the forward PE of 8.66x imply the market is discounting the consensus earnings estimate by a wide margin, and the gap between the +25.5% analyst upside and the -19.0% three-month relative underperformance is the single most important tension in the name.
Bulls vs Bears: HBAN Investment Factors
The bear case currently holds stronger evidence: the stock is in a confirmed downtrend (-16.33% over three months, -12.64% YTD), trading near its 52-week low with accelerating negative momentum, while the revenue surge is tainted by 33% share dilution and flat net margins. However, the bull case is not without merit — a 1.05x P/B, 0.90 PEG, and 3.96% dividend yield suggest deep value, and all 20 analysts maintain a Buy rating with a $19.17 average target. The single most important tension is whether the acquisition-driven revenue growth can translate into per-share earnings accretion; if EPS growth accelerates toward the consensus $1.73 estimate, the stock could re-rate sharply, but if dilution persists and margins compress further, the downtrend will likely continue toward the $14.82 low.
Bullish
- Deep valuation discount to peers: HBAN trades at 1.05x price-to-book and 12.30x trailing PE, versus the 1.3-1.5x P/B and mid-teens PE typical of quality regional banks — a roughly 15-20% discount. The PEG ratio of 0.90 (below 1.0) suggests the market is undervaluing expected earnings growth.
- Analyst consensus sees 25% upside: All 20 covering analysts rate HBAN a Buy (mean rating 1.71), with an average target of $19.17 implying +25.5% upside from $15.27. Even the lowest target of $17.00 sits 11.3% above the current price, and no analyst models a downside scenario.
- Revenue growth accelerating at 37.7%: Q2 2026 revenue surged 37.66% YoY to $4.17 billion, with sequential acceleration from $3.25B (Q4 2025) to $3.77B (Q1 2026) to $4.17B (Q2 2026). This top-line momentum, even if acquisition-driven, provides a larger earnings base for future synergy extraction.
- Attractive 3.96% dividend yield: The dividend yield of 3.96% is roughly double the sector average, backed by a sustainable 45.95% payout ratio and $2.96 billion in trailing free cash flow (an ~11.5% FCF yield on the $25.66B market cap). This offers income investors a compelling entry point.
Bearish
- Acquisition-driven dilution erodes per-share value: Diluted shares outstanding jumped 33% from ~1.48 billion to 1.98 billion, while EPS grew only 11.8% ($0.34 to $0.38) against 37.7% revenue growth. This gap shows the revenue surge is largely purchased and margin-dilutive, not organic.
- Technical breakdown near 52-week lows: At $15.27, HBAN sits just 2.9% above its 52-week low of $14.82 and has fallen 16.33% over three months, underperforming SPY by 19.02 percentage points. The accelerating downtrend (-3.48% 1-month, -16.33% 3-month) signals a falling knife with no base formed.
- ROE and margins below peer standards: ROE of 9.08% is below the 10-12% range typical of well-run regional banks, and net margin of 17.71% is essentially flat YoY despite the revenue surge. Operating margin of 21.50% is down from 23.73% in Q3 2025, indicating integration strain.
- Analyst downgrades signal growing caution: BofA downgraded HBAN to Neutral from Buy on July 27, and Morgan Stanley cut to Equal Weight from Overweight on July 24. These downgrades, alongside the stock's 18% drawdown from July highs, suggest the sell-side consensus may be stale.
HBAN Technical Analysis
HBAN is in a clear, sustained downtrend, with the stock down 0.65% over the past year and 12.64% year-to-date, badly lagging the S&P 500's +15.53% and +11.93% respective returns. At $15.27, the stock trades at just 9.7% of its 52-week range of $14.82 to $19.46 — effectively pinned near the lows, which in technical terms reads as a falling knife rather than a value opportunity until a base forms. The 52-week high of $19.46 was set earlier in the period, and the persistent lower-highs structure confirms sellers remain in control.\n\nShort-term momentum is uniformly negative and, critically, deteriorating: the 1-month change of -3.48% and 3-month change of -16.33% show the decline accelerating rather than stabilizing, with the 3-month figure far worse than the 6-month -9.38% and 1-year -0.65%. This pattern — where shorter lookbacks are progressively worse — signals a fresh leg down rather than mean reversion, and relative strength confirms it: HBAN has underperformed SPY by 19.02 percentage points over three months and 24.57 points year-to-date. The stock's slide from roughly $18.56 in mid-July to $15.27 now represents a nearly 18% drawdown in three months, and the failure to hold the $16.75-17.00 area in mid-September marked a decisive technical breakdown.\n\nKey support sits at the 52-week low of $14.82, just 2.9% below the current price — a break there would likely trigger momentum-driven selling and open a deeper decline. Resistance is layered: the $16.75-17.00 zone (former September support-turned-resistance) is the first hurdle, with the $19.46 high representing the full recovery target. With a beta of 0.972, HBAN is marginally less volatile than the market, so the magnitude of its underperformance is fundamentally driven rather than a high-beta artifact — position sizing should account for the fact that this is a relative-value problem, not a volatility problem, and the max drawdown of -22.06% illustrates the downside risk if support fails.
Beta
0.97
0.97x market volatility
Max Drawdown
-22.1%
Largest decline past year
52-Week Range
$15-$19
Price range past year
Annual Return
-0.7%
Cumulative gain past year
| Period | HBAN Return | S&P 500 |
|---|---|---|
| 1m | -3.5% | +0.2% |
| 3m | -16.3% | +2.9% |
| 6m | -9.4% | +8.4% |
| 1y | -0.7% | +14.9% |
| ytd | -12.6% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HBAN Fundamental Analysis
Revenue is growing explosively at the headline level: Q2 2026 revenue of $4.17 billion represents 37.66% year-over-year growth versus $3.03 billion in Q2 2025, and the sequential progression from $3.25 billion (Q4 2025) to $3.77 billion (Q1 2026) to $4.17 billion (Q2 2026) shows acceleration, not deceleration. However, the quality of this growth warrants scrutiny — diluted shares outstanding jumped from roughly 1.48 billion to 1.98 billion, a 33% increase, indicating the revenue surge is substantially acquisition-driven rather than organic. Segment data shows Consumer & Regional Banking at $1.92 billion and Commercial Banking at $994 million driving the top line, with Treasury/Other a $72 million drag; the investment case hinges on whether management can extract synergies from the expanded base before dilution erodes per-share economics.\n\nProfitability is solid but showing signs of strain from the expansion. Q2 2026 net income of $727 million on a 17.45% net margin and 64.91% gross margin compares favorably to Q2 2025's $536 million and 17.71% net margin, but the net margin is essentially flat year-over-year despite the revenue surge — evidence that acquired revenue is coming at lower incremental margins. Operating margin of 21.50% in Q2 2026 is up from 21.08% a year ago but down from Q3 2025's 23.73%, and the 21.53% operating margin in the key metrics aligns with this compression. EPS of $0.38 in Q2 2026 versus $0.34 in Q2 2025 is only 11.8% growth against 37.7% revenue growth — the dilution gap is the central fundamental issue.\n\nBalance sheet and cash flow metrics are adequate but not exceptional for a regional bank. The debt-to-equity ratio of 0.759 is moderate, ROE of 9.08% is below the 10-12% range typical of well-run regional banks, and ROA of 0.98% is respectable but unspectacular. Free cash flow TTM of $2.96 billion against a $25.66 billion market cap implies a roughly 11.5% FCF yield, which is attractive, but the current ratio of 0.19 reflects the bank's liability-heavy structure rather than a liquidity crisis. The 3.96% dividend yield with a 45.95% payout ratio appears sustainable, though the Q2 2026 cash flow statement shows $6.53 billion in debt repayment and a $10.42 billion net cash decline — aggressive balance sheet management that bears watching.
Quarterly Revenue
$4.2B
2026-06
Revenue YoY Growth
+37.7%
YoY Comparison
Gross Margin
64.9%
Latest Quarter
Free Cash Flow
$3.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HBAN Overvalued?
Because HBAN is profitable (Q2 2026 net income of $727 million), the PE ratio is the appropriate primary metric. The trailing PE of 12.30x against a forward PE of 8.66x implies the market expects earnings to grow roughly 42% — a gap that is unusually wide and signals either significant skepticism about the forward estimate of $1.73 EPS or a market pricing in substantial risk. The PEG ratio of 0.90 (below 1.0) suggests the stock is cheap relative to expected growth, but the trailing PE of 12.30x versus the historical Q2 2026 reading of 11.66x shows the multiple has already expanded modestly even as the price fell, because earnings grew faster than the stock declined.\n\nAgainst regional bank peers, HBAN's 1.05x price-to-book is a meaningful discount to the 1.3-1.5x range typical of quality regional banks, and the 12.30x trailing PE sits below the sector's mid-teens average — roughly a 15-20% discount. The 2.06x price-to-sales ratio is low in absolute terms but reflects the bank's net-interest-income-heavy model. The discount appears partially justified: ROE of 9.08% is below peer averages, the acquisition-driven dilution is a real overhang, and the 17.71% net margin, while stable, is not expanding. However, the 3.96% dividend yield — roughly double the sector average — and the 0.90 PEG suggest the market may be over-penalizing the stock.\n\nHistorically, HBAN's PE has ranged from roughly 7.0x (Q1 2023) to 21.2x (Q4 2023), with the current 12.30x sitting near the middle of that band but well above the 2023 trough. The price-to-book of 1.05x is near the low end of its historical 0.81x-1.20x range over the past three years, which historically has marked accumulation zones. The stock is not at a historical valuation extreme, but the combination of a mid-range PE and a low-end P/B suggests the market is pricing in earnings normalization risk rather than outright distress.
PE
12.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 7x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the acquisition's dilutive impact and margin strain. Diluted shares rose 33% to 1.98 billion, yet EPS grew only 11.8% to $0.38 against 37.7% revenue growth, meaning per-share economics are deteriorating. Net margin of 17.71% is flat YoY and operating margin of 21.50% is down from 23.73% in Q3 2025, indicating acquired revenue carries lower incremental profitability. Additionally, Q2 2026 saw $6.53 billion in debt repayment and a $10.42 billion net cash decline, and the current ratio of 0.19, while typical for a bank, leaves little buffer if funding conditions tighten.
Market and competitive risks are amplified by the stock's persistent underperformance and valuation compression potential. HBAN has lagged SPY by 24.57 percentage points YTD and 19.02 points over three months, with a beta of 0.972 meaning the decline is fundamentally driven, not a high-volatility artifact. The 1.05x P/B already reflects a 15-20% discount to peers, but if ROE (9.08%) fails to improve toward the 10-12% peer range, the discount could widen further. Recent analyst downgrades from BofA and Morgan Stanley highlight growing skepticism, and the uniform absence of a sell rating among analysts may indicate anchored expectations rather than genuine confidence.
Worst-case scenario: a failure to hold the $14.82 52-week low would trigger momentum-driven selling, potentially extending the decline toward the $13-14 range, representing a 8-15% loss from the current $15.27. A more severe outcome — if integration synergies fail to materialize and EPS estimates are cut — could push the stock toward its historical low-end P/B of 0.81x, implying a price near $11.70 (a 23% decline). The max drawdown of -22.06% illustrates the realistic downside if support breaks and fundamental deterioration continues.
FAQ
The most severe risk is continued EPS dilution: diluted shares rose 33% to 1.98 billion while EPS grew only 11.8%, and if integration synergies fail, per-share earnings could stagnate. Second, technical breakdown risk: the stock is 2.9% above its $14.82 52-week low, and a break below could trigger momentum selling toward $13-14. Third, margin compression: net margin of 17.71% is flat YoY and operating margin fell from 23.73% to 21.50%, signaling integration strain. Fourth, analyst downgrade risk: BofA and Morgan Stanley recently cut ratings, and further downgrades could pressure the stock. These risks are ranked in order of severity, with dilution being the most fundamental threat to the investment thesis.
Our 12-month forecast has three scenarios: bull case (25% probability) targeting $19.17-$22.50 if integration succeeds and EPS approaches $1.73; base case (50% probability) targeting $16.75-$19.17 as the stock stabilizes and gradually recovers toward the analyst average; and bear case (25% probability) targeting $14.82-$17.00 if dilution persists and support breaks. The base case is most likely, assuming net margin holds around 17-18% and the dividend attracts income buyers. The key assumption is that Q3 earnings show sequential EPS improvement without further margin deterioration. The wide target range ($17.00-$22.50) reflects genuine uncertainty about the earnings trajectory.
HBAN appears undervalued on most metrics: 1.05x P/B versus the 1.3-1.5x peer range, 12.30x trailing PE versus mid-teens sector average, and a 0.90 PEG below 1.0. The forward PE of 8.66x implies the market expects 42% EPS growth to $1.73, yet the stock trades as if that growth is unlikely. However, the discount is partially justified by ROE of 9.08% (below the 10-12% peer range) and flat net margins despite 37.7% revenue growth. The P/B is near the low end of its historical 0.81x-1.20x range, which has historically marked accumulation zones. Overall, the stock is modestly undervalued relative to history and peers, but not deeply so given fundamental headwinds.
HBAN offers a compelling risk/reward for value-oriented investors: the stock trades at 1.05x book and 12.30x trailing PE, well below peer averages, with a 3.96% dividend yield and a 0.90 PEG. Analysts unanimously rate it a Buy with a $19.17 average target, implying 25.5% upside. However, the stock is in a confirmed downtrend (-16.33% over three months) and sits just 2.9% above its 52-week low, so near-term downside risk remains. The biggest risk is continued EPS dilution from the 33% share increase. It is a good buy for long-term income investors who can tolerate volatility and wait for integration synergies, but short-term traders should wait for a base to form above $16.75.
HBAN is better suited for long-term investment (minimum 12-18 months) given its deep-value profile, 3.96% dividend yield, and acquisition integration story that requires time to play out. The beta of 0.972 indicates market-like volatility, but the stock's -22.06% max drawdown and current downtrend make short-term trading risky without a defined base. The dividend yield and 45.95% payout ratio provide income support during the wait, and the 0.90 PEG suggests growth is undervalued. Short-term traders should wait for a confirmed reversal above $16.75-17.00 resistance before entering. A suggested minimum holding period of 12 months aligns with the time needed for integration synergies to materialize and for the stock to potentially re-rate toward analyst targets.